Icon
+91 94997 68112
Login Register

Invega Sustenna - (39 mg/0.25 mL, 78 mg/0.5 mL, 117 mg/0.75 mL, 156 mg/mL and 234 mg/1.5 mL ; Suspension Extended Release)

Paliperidone Palmitate Janssen Pharma
39 mg/0.25 mL, 78 mg/0.5 mL, 117 mg/0.75 mL, 156 mg/mL and 234 mg/1.5 mL ; Suspension Extended Release
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
None None
Treatment of schizophrenia in adults. Treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants
Yes
**** ** *** ***** ** **** **** ** **** ****** '*** (*** **, ****) *** *** ************ *********. ** ****** **** **** **** ******* ** **** ****. *****, ***** *** ************* ***** * **** ** **** ****** '*** (*** **, ****) *** **** *********. ** ****** **** **** ***** *** ************* ******* ** *** **** *** **** **** ************. ****** **** : ******
Invega Sustenna Patent 1 Patent 2
**** *** ********* **** ** ** *** **
***** *** ********* **** ** ** *** **
************* *** ********* **** ** *** **, ****
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ ********* **** **, **** **** ** ** *** ** ******** ************ ** *** **, ****
***** ** \ ** *** *, **** **** ** ** *** ** **** ** *** **, ****
************* ** \ ** **** **, **** ******* ********* ******** ******* *** **** *** *** ****
  1. *** *, **** : **** ******** ******* ***** *** **** ** **** ****** '*** (*** **, ****).
  2. *** **, **** : ******* ***** * **** ******* **** ** ******** ***** ** ** ** ****** '***(*** **, ****).
  3. *** **, **** : ***** ******** ******* ***** *** **** ** **** ****** '*** (*** **, ****).
  4. *** *, **** : ******* ***** * **** ******* ***** ** ****** '***(*** **, ****).
  5. *** *, **** : ************* (************) ******** ******* ***** **'* **** ** **** ****** '*** (*** **, ****)
  6. *** **, **** : ******* ***** * **** ******* ************* ** ****** '***(*** **, ****)
  7. *** **, **** : ****** ****** ******** ******* ********* *** **** ** ****** **** ****** '***.
  8. *** **, **** : **** **** ********** ******* ******* ** *** *** ***** ******** ******* ** *****.
  9. *** **, **** : **** ******** ** *** ** ******* ******* **** *** ***** ********* ******* ** *** **, ****.
  10. *** **, **** : ******* ****** **** ****** **** ****** '*** ******** ** *** **, ****.
  11. *** **, **** : ***** **** *** **** ******* ******* ** ** ** *** ***** ********* ******* ** *****.
  12. *** **, **** : ***** ******** ** *** ** ******* ******* **** *** ***** ********* ******* ** *** **, ****.
  13. *** **, **** : ******(*****) ******** ******* ********* *** **** ** ******.
  14. *** **, **** : ******* **** ******(*****) **** ****** '*** ******** ** *** **, ****.
  15. *** **, **** : *** **** ******* ****** (*****) *** ************* *** **************** ******, *** ** ***** **** ******** **** ** (** *** **** ******* ***** - **-****)
  16. *** **, **** : ********* ** ***** *********, ****** *** **** ** ** **** ************ ** ****** ** '***..
  17. *** *, **** : ** *** ******** *** ******** ******* **** *** *****. ***** **** *** ***** **** **** ** **.
  18. *** **, **** : ****** *** ******** **'* ***** ********* ** **.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.